98%
921
2 minutes
20
Alzheimer's disease (AD) is defined by the presence of amyloid-β (Aβ) and tau protein aggregates. However, increasing data is suggesting that brain network alterations rather than protein deposition could account for the early pathogenesis of the disease. In the present study, we performed extracellular field recordings in the CA1/subiculum area of the hippocampus from 30 days old J20-TG-AD mice. Here, we found that theta oscillations were significantly less rhythmic than those recorded from control group. In addition, J20 mice displayed significantly less theta-gamma cross-frequency coupling (CFC) as peak modulation indexes for slow (25-45 Hz) and fast (150-250 Hz) gamma frequency oscillations were reduced. Because inhibitory parvalbumin (PV) cells play a vital role in coordinating hippocampal theta and gamma oscillations, whole-cell patch-clamp recordings and extracellular stimulation were performed to access their intrinsic and synaptic properties. Whereas neither the inhibitory output of local interneurons to pyramidal cells (PCs) (inhibitory→PC) nor the excitatory output of PCs to PV cells (PC→PV) differed between control and J20 animals, the intrinsic excitability of PV cells was reduced in J20 mice compared to controls. Interestingly, optogenetic activation of PV interneurons which can directly drive theta oscillations in the hippocampus, did not rescue CFC impairments, suggesting the latter did not simply result from alteration of the underlying theta rhythm. Altered young J20 mice was characterized by the presence of β-CTF, but not with Aβ accumulation, in the hippocampus. Importantly, the β secretase inhibitor AZD3839-AstraZeneca significantly rescued the abnormal early electrophysiological phenotype of J20 mice. In conclusion, our data show that brain network alterations precede the canonical Aβ protein deposition and that, such alterations can be related to β-CTF fragment.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5952042 | PMC |
http://dx.doi.org/10.3389/fncel.2018.00121 | DOI Listing |
Int J Neuropsychopharmacol
August 2025
Division of Systems Medical Science, Center for Medical Science, Fujita Health University, Toyoake, Aichi 470-1192, Japan.
Background: The hippocampal dentate gyrus (DG) is a critical region that contributes to recent and remote memory. Granule cells within this region, in which adult neurogenesis occurs, undergo dynamic and reversible maturation via genetic and environmental factors during adulthood. A pseudo-immature state of DG granule cells, called immature DG (iDG), has been observed in the adult mice of certain mutant strains, which are considered animal models of neuropsychiatric and neurodegenerative disorders, such as intellectual disability, schizophrenia, autism, and Alzheimer's disease.
View Article and Find Full Text PDFNeurosci Lett
August 2025
Department of Pharmacology, Health Science Center, Ningbo University, Ningbo, Zhejiang 315211, China. Electronic address:
Background: Hyperexcitability of hippocampal CA1 pyramidal neurons contributes to cognitive deficits in Alzheimer's disease (AD). Tropisetron, a 5-HT receptor antagonist and partial α7 nicotinic acetylcholine receptor (α7nAChR) agonist, has shown neuroprotective effects, but its impact on hippocampal neuronal excitability remains unclear.
Objective: This study aimed to examine the effects of tropisetron on CA1 pyramidal neurons and fast-spiking interneurons in wild-type (WT) and hAPP-J20 AD model mice, a transgenic model for early-onset AD.
Exp Neurol
August 2025
Department of Biomedical Imaging and Radiological Sciences, National Yang Ming Chiao Tung University, Taipei, Taiwan. Electronic address:
Alzheimer's disease (AD) is characterized by amyloid-β (Aβ) plaque accumulation and neurofibrillary tangles, leading to neuroinflammation, synaptic dysfunction, and cognitive decline. Despite extensive research, current therapies for AD show limited efficacy. Low-intensity pulsed ultrasound (LIPUS) has emerged as a promising non-invasive therapeutic approach due to its neuroprotective and immunomodulatory properties.
View Article and Find Full Text PDFAging Dis
July 2025
Laboratory of Neurobiology of Aging, Institute of Biology and Experimental Medicine (IBYME), National Research Council (CONICET) and IBYME Foundation, Buenos Aires, Argentina.
Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder, characterized by amyloid beta (Aβ) plaques, neuroinflammation and cognitive impairment. Metabolic disturbances, particularly brain insulin resistance, are increasingly recognized as central features of AD pathophysiology. Astrocytes, essential for brain energy metabolism, exhibit a loss of homeostatic functions in AD, possibly promoting neurodegeneration.
View Article and Find Full Text PDFBrain Behav Immun
October 2025
Department of Pharmacology, University of Oxford, Oxford OX1 3QT, UK.
Traumatic brain injury (TBI) significantly contributes to morbidity and mortality worldwide, often leading to cognitive decline. Although there is a recognised link between TBI and the acceleration of Alzheimer's disease (AD), the precise biological mechanisms driving this relationship are not fully understood. While several studies have investigated TBI in AD mouse models, none have examined the role of systemic inflammation in this context.
View Article and Find Full Text PDF